Clinical trial · Observational
Failure to Adjuvant Therapy After Pancreatic Resection for Pancreatic Cancer
Failure to Adjuvant Therapy After Pancreatic Resection for Pancreatic Cancer: a Real Life Scenario
NCT03788382CI-TRIAL-00076831FOUNTAINcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the rate of patients submitted to pancreatic resection for pancreatic cancer, who fail to access to adjuvant therapy or do not complete adjuvant therapy. The purpose is to give an overview concerning the most frequent conditions and/or reasons associated with failure or omission of adjuvant therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Malignant Neoplasm Primary | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Rate of patients who fail to receive adjuvant therapy and reasons for that
- timeFrame
- 6 months
- description
- The amount of patients who will not receive adjuvant therapy after pancreatic resection for malignancy (when do indication exists) will be recorded
- measure
- Rate of patients who fail to complete adjuvant therapy and reasons for that
- timeFrame
- 9 months
- description
- The amount of patients who will not complete adjuvant therapy after pancreatic resection for malignancy will be recorded
Secondary outcomes (1)
- measure
- Disease free survival of patients enrolled
- timeFrame
- 18 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic diagnosis of pancreatic cancer Exclusion Criteria: * Non exocrine pancreatic tumors * Periampullary malignancies
References
Publications (1)
- DERIVEDPaiella S, Malleo G, Lionetto G, Cattelani A, Casciani F, Secchettin E, De Pastena M, Bassi C, Salvia R. Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use-A Prospective Real-Life Study. Ann Surg Oncol. 2024 May;31(5):2892-2901. doi: 10.1245/s10434-024-14951-4. Epub 2024 Jan 29. PMID 38286884